ArticleJournal of orthopaedic surgery and research2026
The clinical role of lncRNA PRKG1-AS1 in lumbar disc degeneration and its mechanism in regulating inflammation and ferroptosis via miR-218-5p.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLumbar disc degeneration (LDD) is a common spinal disorder that predisposes patients to lumbar disc herniation (LDH) and causes chronic low back pain. Its pathogenesis remains incompletely understood. This study investigated the clinical relevance of PRKG1-AS1 in LDD and explored its regulation of LDD progression through miR-218-5p, providing experimental support for LDD targeted treatment.
methodsThis study enrolled 128 LDD patients and 102 healthy individuals to measure serum levels of PRKG1-AS1 and analyze its associations with clinical parameters. A degeneration model of human nucleus pulposus cells (hNPCs) was established using TNF-α induction. The effects of PRKG1-AS1 on cell proliferation, metabolic balance, ferroptosis, inflammation, and oxidative stress were assessed through transfection experiments. Additionally, dual-luciferase reporter assays confirmed the targeted binding interactions.
resultsSerum PRKG1-AS1 showed strong diagnostic value for LDD. Its expression was closely related to disease severity and patient functional status, making it an independent risk factor for progression from LDD to LDH. Overexpressing PRKG1-AS1 significantly improved the TNF-α-induced degenerative phenotype, enhanced hNPCs proliferation, restored metabolic balance, reduced ferroptosis, and alleviated inflammation and oxidative stress damage. Dual-luciferase assays confirmed that PRKG1-AS1 directly binds to miR-218-5p, and miR-218-5p targets CUL3. PRKG1-AS1 exerted a protective effect in LDD progression via the miR-218-5p/CUL3 axis.
conclusionSerum PRKG1-AS1 may serve as a promising biomarker for early detection and prediction of LDD progression. It modulates inflammation and ferroptosis in nucleus pulposus cells through the PRKG1-AS1/miR-218-5p/CUL3 axis, thereby inhibiting the LDD development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.